7QI8
CRYSTAL STRUCTURE OF LYSYL-TRNA SYNTHETASE FROM Mycobacterium tuberculosis COMPLEXED WITH L-LYSINE AND INHIBITOR
7QI8 の概要
| エントリーDOI | 10.2210/pdb7qi8/pdb |
| 関連するPDBエントリー | 7QH8 7QHN |
| 分子名称 | Lysine--tRNA ligase 1, LYSINE, 2-azanyl-6-[(1~{S},7~{S})-2,2-bis(fluoranyl)-7-oxidanyl-cycloheptyl]-4-methoxy-7~{H}-pyrrolo[3,4-d]pyrimidin-5-one, ... (4 entities in total) |
| 機能のキーワード | ligase, mycobacterium tuberculosis, atp binding |
| 由来する生物種 | Mycobacterium tuberculosis H37Rv |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 58605.08 |
| 構造登録者 | Dawson, A.,Robinson, D.A.,Tamjar, J.,Wyatt, P.,Green, S. (登録日: 2021-12-14, 公開日: 2022-10-19, 最終更新日: 2024-02-07) |
| 主引用文献 | Green, S.R.,Davis, S.H.,Damerow, S.,Engelhart, C.A.,Mathieson, M.,Baragana, B.,Robinson, D.A.,Tamjar, J.,Dawson, A.,Tamaki, F.K.,Buchanan, K.I.,Post, J.,Dowers, K.,Shepherd, S.M.,Jansen, C.,Zuccotto, F.,Gilbert, I.H.,Epemolu, O.,Riley, J.,Stojanovski, L.,Osuna-Cabello, M.,Perez-Herran, E.,Rebollo, M.J.,Guijarro Lopez, L.,Casado Castro, P.,Camino, I.,Kim, H.C.,Bean, J.M.,Nahiyaan, N.,Rhee, K.Y.,Wang, Q.,Tan, V.Y.,Boshoff, H.I.M.,Converse, P.J.,Li, S.Y.,Chang, Y.S.,Fotouhi, N.,Upton, A.M.,Nuermberger, E.L.,Schnappinger, D.,Read, K.D.,Encinas, L.,Bates, R.H.,Wyatt, P.G.,Cleghorn, L.A.T. Lysyl-tRNA synthetase, a target for urgently needed M. tuberculosis drugs. Nat Commun, 13:5992-5992, 2022 Cited by PubMed Abstract: Tuberculosis is a major global cause of both mortality and financial burden mainly in low and middle-income countries. Given the significant and ongoing rise of drug-resistant strains of Mycobacterium tuberculosis within the clinical setting, there is an urgent need for the development of new, safe and effective treatments. Here the development of a drug-like series based on a fused dihydropyrrolidino-pyrimidine scaffold is described. The series has been developed against M. tuberculosis lysyl-tRNA synthetase (LysRS) and cellular studies support this mechanism of action. DDD02049209, the lead compound, is efficacious in mouse models of acute and chronic tuberculosis and has suitable physicochemical, pharmacokinetic properties and an in vitro safety profile that supports further development. Importantly, preliminary analysis using clinical resistant strains shows no pre-existing clinical resistance towards this scaffold. PubMed: 36220877DOI: 10.1038/s41467-022-33736-5 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (2.2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






